Humanity Health and Quest Diagnostics have launched a biological age analysis add-on for select health profile tests in the US, allowing users to assess aging biomarkers using routine blood samples.
Pillar Biosciences, LC-SCRUM-Asia, and LSI Medience will collaborate on a two-year, 2,000-patient liquid biopsy lung cancer screening project in Japan, using cfDNA and cfRNA testing.
The CLEAR-AD study found significant performance differences among nine commercial plasma p-tau217 assays for Alzheimer’s, underscoring the need for platform-specific calibration to ensure diagnostic accuracy.
The company says its US business combines automated kit manufacturing, fulfillment, sample logistics, and digital workflow technology into a single diagnostic testing platform.
Epredia will incorporate Leeds NHS Trust’s TANGO quality control technology into pathology slides, aiming to enhance staining consistency for digital pathology and AI diagnostics. Integration is set to begin in late 2026.
Researchers have launched LipidLibrarian, an open-source tool that integrates data from major lipid databases to streamline diagnostic marker identification.
The assay is designed to detect minimal residual disease with greater sensitivity than conventional flow cytometry.
Algocyte has launched the PROXIMA Mobile Health Station, a portable device that uses AI and sensors for at-home blood analysis from finger-prick samples, with UKCA regulatory approval and ongoing evaluation.
BRAINBox Solutions has secured financing from Pivotal Capital Partners and New Horizon Bank to advance its point-of-care and lab-based concussion diagnostic devices for traumatic brain injury.
SCIEX has launched the ExionLC MD system and updated SCIEX OS software, featuring workflow automation and high-performance UHPLC, to help clinical labs improve productivity, as announced at the ADLM meeting.
Astorg has completed its acquisition of Thermo Fisher’s global microbiology business, establishing an independent diagnostics company. Dirk Bontridder has been named CEO.
Zepto Life Technology received up to $8.9 million from NIAID to develop a plasma cell-free DNA liquid biopsy platform aimed at improving diagnosis of invasive fungal infections.
The cobas liat system delivers PCR results in 15 minutes, detecting and differentiating between three Bordetella pathogens including whooping cough.
The automated urinalysis system integrates chemistry and microscopy to help labs manage higher testing volumes and reduce manual reviews to under 3%, according to the company.